secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-103034
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics reports FY 2025 net income of $5.7M from continuing ops; cash runway through Q3 2026
--------------------------------------------------------------------------------

- Full-year 2025 net income from continuing ops $5.7M vs net loss of $125.8M in 2024; Q4 net loss $15.3M.
- Cash and equivalents $45.8M as of Dec 31, 2025; expects to fund operations through Q3 2026.
- SER-155 IST for immune checkpoint-related enterocolitis fully enrolled; data expected Q2 2026.
- SER-603 for IBD in IND-enabling activities; seeking partnerships for clinical advancement.
- Richard Kender appointed Executive Chair and interim CEO; company prioritized inflammatory/immune programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/0001193125-26-103034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/d98522d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-103034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer